Literature DB >> 21263251

Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study.

Kohei Fujita1, Hidetaka Yamamoto, Takayuki Matsumoto, Minako Hirahashi, Masaki Gushima, Junji Kishimoto, Ken-ichi Nishiyama, Tomoaki Taguchi, Takashi Yao, Yoshinao Oda.   

Abstract

Sessile serrated adenoma (SSA), also referred to as sessile serrated polyp, has been proposed as a precursor lesion to microsatellite unstable carcinoma. However, the mechanism of stepwise progression from SSA to early invasive carcinoma has been unclear. The purpose of this study was to elucidate the histologic characteristics and possible role of p53, β-catenin, BRAF, KRAS, and PIK3CA in the development and progression of SSA. We analyzed 12 cases of SSA with neoplastic progression (SSAN), including 7 cases of intraepithelial high-grade dysplasia (HGD) and 5 cases of submucosal invasive carcinoma, and compared them with 53 SSAs and 66 hyperplastic polyps (HPs) by immunohistochemistry and gene mutation analysis. Histologically, 75% (9 of 12) of SSANs showed tubular or tubulovillous growth patterns rather than serrated ones in the HGD/intramucosal carcinoma component. All 5 SSANs with invasive carcinoma lost their serrated structure and developed increased extracellular mucin in their submucosal carcinoma component, a consistent feature of mucinous adenocarcinoma. Nuclear accumulations of β-catenin and p53 were observed in 50% (6 of 12) and 41.7% (5 of 12) of SSANs, respectively, and were exclusively present in HGD/carcinoma areas. By contrast, neither nuclear β-catenin nor p53 expressions were seen in HPs or SSAs (P<0.0001). BRAF mutations (V600E) were observed in 45.8% (11 of 24) of HPs, 60.9% (14 of 23) of SSAs, and 63.6% (7 of 11) of SSANs, and were equally found in both SSA and carcinoma/HGD areas of the individual SSANs. KRAS exon 1 mutations were uncommon in all 3 groups (4.2%, 4.4%, and 0%, respectively). No mutations of PIK3CA exon 9 or exon 20 were found in any cases that were examined. These findings suggest that BRAF mutations may be associated with the pathogenesis of SSA, but progression to HGD or early invasive carcinoma may be associated with other factors, such as alterations of p53 and β-catenin. In addition, our histologic observations suggest a possible close association between SSAN and mucinous adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263251     DOI: 10.1097/PAS.0b013e318205df36

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  40 in total

1.  Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression.

Authors:  Gabriel Acosta-Gonzalez; Madhu Ouseph; Kara Lombardo; Shaolei Lu; Jonathan Glickman; Murray B Resnick
Journal:  Hum Pathol       Date:  2018-08-31       Impact factor: 3.466

2.  Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon.

Authors:  Baojin Fu; Shinichi Yachida; Richard Morgan; Yi Zhong; Elizabeth A Montgomery; Christine A Iacobuzio-Donahue
Journal:  Am J Clin Pathol       Date:  2012-09       Impact factor: 2.493

3.  The role of APC in WNT pathway activation in serrated neoplasia.

Authors:  Jennifer Borowsky; Troy Dumenil; Mark Bettington; Sally-Ann Pearson; Catherine Bond; Lochlan Fennell; Cheng Liu; Diane McKeone; Christophe Rosty; Ian Brown; Neal Walker; Barbara Leggett; Vicki Whitehall
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

4.  Clinicopathologic and outcome study of sessile serrated adenomas/polyps with serrated versus intestinal dysplasia.

Authors:  Odise Cenaj; Joanna Gibson; Robert D Odze
Journal:  Mod Pathol       Date:  2017-12-22       Impact factor: 7.842

5.  Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.

Authors:  Reiko Kumagai; Kenichi Kohashi; Shunsuke Takahashi; Hidetaka Yamamoto; Minako Hirahashi; Kenichi Taguchi; Kenichi Nishiyama; Yoshinao Oda
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

6.  IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.

Authors:  Takafumi Naito; Katsuhiko Nosho; Miki Ito; Hisayoshi Igarashi; Kei Mitsuhashi; Shinji Yoshii; Hironori Aoki; Masafumi Nomura; Yasutaka Sukawa; Eiichiro Yamamoto; Yasushi Adachi; Hiroaki Takahashi; Masao Hosokawa; Masahiro Fujita; Toshinao Takenouchi; Reo Maruyama; Hiromu Suzuki; Yoshifumi Baba; Kohzoh Imai; Hiroyuki Yamamoto; Shuji Ogino; Yasuhisa Shinomura
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  A significant imbalance in mitosis versus apoptosis accelerates the growth rate of sessile serrated adenoma/polyps.

Authors:  Akira Endo; Hirotaka Koizumi; Makiko Takahashi; Tomohiro Tamura; Shinobu Tatsunami; Yoshiyuki Watanabe; Masayuki Takagi
Journal:  Virchows Arch       Date:  2013-01-06       Impact factor: 4.064

8.  Distinct WNT/β-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum.

Authors:  Takashi Murakami; Hiroyuki Mitomi; Tsuyoshi Saito; Michiko Takahashi; Naoto Sakamoto; Naoshi Fukui; Takashi Yao; Sumio Watanabe
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

9.  Risk of Metachronous Advanced Neoplastic Lesions in Patients with Sporadic Sessile Serrated Adenomas Undergoing Colonoscopic Surveillance.

Authors:  Lisandro Pereyra; Rafael Zamora; Estanislao Jesús Gómez; Carolina Fischer; Guillermo Nicolas Panigadi; Raquel González; Maximiliano Bun; José Manuel Mella; Mariana Omodeo; Pablo Luna; Marcelo Amante; Gabriel Casas; Silvia Pedreira; Daniel Cimmino; Luis Boerr
Journal:  Am J Gastroenterol       Date:  2016-04-12       Impact factor: 10.864

Review 10.  Pathological features of the sessile serrated adenoma/polyp with special references of its carcinogenesis.

Authors:  Ryo Wada; Toshio Morimoto; Tatsuya Inayoshi
Journal:  Med Mol Morphol       Date:  2014-04-20       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.